AI Model Predicted Breast Cancer Risk in Study
Researchers at NYU Langone Health tested a tool that tracks breast tissue changes to estimate risk over five years.
Updated on Oct. 11, 2026 in Cancer
Live Poll
Would you trust an AI tool to help determine your personal cancer screening schedule?
NYU Langone Health researchers developed an artificial intelligence model to identify breast cancer risk by analyzing patterns in 3D mammograms. This preliminary study evaluated the tool's ability to forecast risk over a five-year period.
Why it matters
The model aims to flag individuals who face an increased risk of breast cancer but might not be detected through traditional risk assessments like family history. By identifying these patterns, it could potentially improve early detection efforts.
This preliminary study utilized a dataset of 313,000 mammograms from 161,000 women to train an AI model. The system evaluates 3D mammographic imagery to predict breast cancer development within a five-year window.
The players
NYU Langone Health
A New York City-based academic medical center that conducted the research.
Perlmutter Cancer Center
The specialized cancer research and treatment facility involved in the study at NYU Langone Health.
The details
The AI tool functions by monitoring longitudinal changes in breast tissue composition that are captured during routine 3D mammography screenings. Unlike standard assessments that rely heavily on static factors like family history, this model identifies subtle, evolving patterns within the tissue. By analyzing these serial images, the system attempts to flag risk markers that might otherwise go unnoticed during standard diagnostic review.
Timeline
October 11, 2026: The study was published in the American Journal of Roentgenology.
Health Landscape
This research follows the broader industry trend of integrating machine learning into radiological practice to augment traditional diagnostic imaging. It sits within the pipeline of emerging technologies seeking to enhance early detection accuracy compared to standard current clinical benchmarks.
Because this tool is not yet FDA-authorized for clinical use, it does not currently influence local diagnostic procedures in New York City. Patients should continue to follow their physician's recommendations regarding routine screening intervals and established risk assessments.
The takeaway
While this AI development shows promise for future risk forecasting, it remains an experimental model that is not yet ready for hospital use. Continue to prioritize your standard screening schedule and discuss any personal concerns about your breast cancer risk with your primary care physician.
Further reading
Learn more about the latest innovations in screening and detection in our Cancer section.
Live Poll
Would you trust an AI tool to help determine your personal cancer screening schedule?
